Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (ENSC) is a clinical-stage pharmaceutical company focused on developing innovative solutions for severe pain relief while simultaneously reducing the potential for opioid misuse, abuse, and overdose ¹. The company's core business model revolves around its proprietary Trypsin Activated Abuse Protection (TAAP) platform and Multi-Pill Abuse Resistant (MPAR®) platform, which are designed to improve the safety of prescription drugs, primarily opioid pain products and opioid use disorder products ². ENSC generates revenue primarily from federal grants, with $5.066 million ³ in federal grants for the year ended December 31, 2025, compared to $5.210 million ⁴ for the year ended December 31, 2024. The company has not yet generated any revenue from product sales and anticipates incurring significant financial losses for the foreseeable future ⁵.

The TAAP platform utilizes a novel molecular delivery technology designed to deter prescription opioid abuse at the molecular level by releasing clinically effective opioid drugs only when exposed to specific physiological conditions, such as the digestive enzyme trypsin ⁶. This approach aims to prevent abuse through intravenous or intranasal routes, as preclinical studies indicate PF614 does not readily convert to oxycodone in the bloodstream and trypsin is absent in the nasal passage ⁷. The MPAR® platform, when combined with TAAP prodrugs, is designed to limit the bioavailability of active opioid following co-ingestion of multiple doses, whether inadvertent or intentional, by inhibiting trypsin at higher doses, thereby preventing metabolic activation and averting overdose ⁸.

ENSC's lead product candidate, PF614, is a TAAP oxycodone prodrug currently in Phase 3 clinical development for the treatment of moderate to severe pain following abdominoplasty, with enrollment beginning in December 2025 ⁹. PF614 is designed as a delayed-release prodrug that releases oxycodone over 4 to 6 hours ¹⁰ after oral ingestion. Clinical data from Phase 1 and Phase 1b studies demonstrated PF614 was well-tolerated at doses up to 200 mg ¹¹ and that 100 mg PF614 was bioequivalent to 40 mg OxyContin ¹² under both fasted and fed conditions. Intranasal human abuse potential studies showed PF614 powder produced a statistically significant lower peak "drug liking" (Emax) compared to intranasal crushed IR oxycodone (p = 0.0133) ¹³. Oral human abuse potential studies also showed statistically lower "Drug Liking" for PF614 at low and mid doses (p<0.0001 and p=0.0025, respectively) ¹⁴. An efficacy study, PF614-201, completed in December 2023, demonstrated that both 50 mg and 100 mg doses of PF614 decreased the intensity of pain ¹⁵.

PF614-MPAR, a combination of PF614 and nafamostat, is in Phase 1b clinical development ¹⁶. Initial data from the PF614-MPAR-101 overdose protection study, reported in May 2022, demonstrated reduced release of oxycodone from PF614 in a simulated overdose situation when combined with nafamostat ¹⁷. Part B of this study, completed in March 2023, showed that while 1 or 2 dose units of PF614-MPAR 25 mg delivered oxycodone equivalently to PF614 without MPAR®, simultaneous administration of 3 dose units or greater resulted in reduced oxycodone in circulation ¹⁸. A significant decrease (p<0.00333) ¹⁹ in maximal oxycodone plasma concentration was observed at 8 dose units of PF614-MPAR 25 mg compared to unprotected PF614 200 mg ²⁰. PF614-MPAR was granted Breakthrough Therapy designation by the FDA in January 2024 ²¹. A second three-part trial, PF614-MPAR-102, initiated in December 2024, is examining a 100 mg dose of PF614-MPAR ²². Beyond opioids, the company is also applying its TAAP and MPAR® technology to a methadone prodrug for Opioid Use Disorder and exploring nafamostat for infection and pulmonary lung diseases ²³.

For the fiscal year ended December 31, 2025, ENSC reported federal grants revenue of $5.066 million ²⁴, a decrease from $5.210 million ²⁵ in 2024. Total operating expenses increased to $15.307 million ²⁶ in 2025 from $11.940 million ²⁷ in 2024. This resulted in a loss from operations of $10.240 million ²⁸ in 2025, compared to $6.730 million ²⁹ in 2024. Net loss for 2025 was $10.176 million ³⁰, an increase from $7.987 million ³¹ in 2024. Diluted EPS was $(3.98) ³² in 2025, compared to $(11.45) ³³ in 2024. As of December 31, 2025, cash and cash equivalents were $4.310 million ³⁴. Total current liabilities were $4.567 million ³⁵ and total liabilities were $4.567 million ³⁶. Notes payable and accrued interest totaled $306,708 ³⁷.

The year-over-year comparison shows a decrease in federal grant revenue by $0.143 million ³⁸, primarily due to a $2.1 million ³⁹ decrease in OUD grant funding offset by a $2.0 million ⁴⁰ increase in MPAR grant funding. Research and development expenses increased by $3.157 million ⁴¹ to $10.376 million ⁴² in 2025, driven by increased clinical and pre-clinical programs for PF614 and PF614-MPAR. General and administrative expenses increased by $0.209 million ⁴³ to $4.930 million ⁴⁴. Net cash used in operating activities increased to $7.806 million ⁴⁵ in 2025 from $7.502 million ⁴⁶ in 2024. Net cash provided by financing activities was $8.738 million ⁴⁷ in 2025, down from $9.881 million ⁴⁸ in 2024.

Significant operational developments during the period include the initiation of the pivotal Phase 3 trial for PF614 (PF614-301) in July 2025, with enrollment beginning in December 2025 ⁴⁹. A second three-part Phase 1b trial for PF614-MPAR (PF614-MPAR-102) began in December 2024 ⁵⁰. The company also completed a Series B Preferred Stock financing on November 13, 2025, raising $4.0 million ⁵¹ through the issuance of 4,000 shares of Series B Preferred Stock and warrants ⁵². Additionally, in April 2025, the company completed a warrant inducement offer, generating approximately $2.2 million ⁵³ in gross proceeds from the exercise of warrants and payment for new common warrants ⁵⁴. In March 2025, a registered direct offering and concurrent private placement generated approximately $1.1 million ⁵⁵ in gross proceeds from the sale of common stock and pre-funded warrants ⁵⁶.

Management explicitly states that the company does not expect to generate any significant revenue from product sales for the next few years ⁵⁷. The company anticipates continuing to incur significant losses for the foreseeable future as it advances its research and development efforts and seeks regulatory approvals for its product candidates ⁵⁸.

A major growth area for the company is the continued clinical development of its lead product candidate, PF614. The pivotal Phase 3 trial, PF614-301, examining the efficacy of PF614 in post-operative acute pain following abdominoplasty, initiated in July 2025, with enrollment beginning in December 2025 ⁵⁹. The company believes PF614 has the potential to offer a safer alternative to existing abuse-deterrent opioid products ⁶⁰. The FDA has provided guidance that an acute pain indication may be appropriate for PF614, which could potentially reduce development timelines and costs compared to pursuing a chronic pain indication ⁶¹. The company also intends to pursue patent term extension for one patent covering PF614 for up to five years ⁶² in the United States, and believes PF614 will be eligible for five-year New Chemical Entity (NCE) regulatory exclusivity upon approval ⁶³.

Another key growth vector is the development of PF614-MPAR, which has been granted Breakthrough Therapy designation by the FDA in January 2024 ⁶⁴. A second three-part Phase 1b trial, PF614-MPAR-102, initiated in December 2024, is designed to evaluate overdose protection across a range of dosages and is expected to be completed in 2026 ⁶⁵. The company is clinically testing MPAR® in partnership with Quotient Sciences to find a formulation that allows normal conversion to oxycodone at prescribed doses but reduces conversion at higher, overdose levels ⁶⁶. The company also believes PF614-MPAR will be eligible for three-year clinical investigation (CI) regulatory exclusivity under the Hatch-Waxman Act upon approval ⁶⁷. Beyond these, the company is applying its TAAP and MPAR® technology to a methadone prodrug for Opioid Use Disorder and exploring nafamostat for infection and pulmonary lung diseases ⁶⁸.

Operationally, the company expects its research and development expenses to increase once the Phase 3 clinical trial for PF614 begins, contingent on its ability to raise sufficient capital ⁶⁹. General and administrative expenses are expected to approximate current levels ⁷⁰. The company anticipates incurring additional costs associated with operating as a public company, including legal, accounting, insurance, and investor relations expenses ⁷¹.

Regarding capital allocation, the company's existing cash and cash equivalents of $4.310 million ⁷² as of December 31, 2025, are estimated to fund operating expenses and capital expenditure requirements into the second quarter of 2026 ⁷³. The remaining cash funding under the MPAR federal research grant totaled $7.4 million ⁷⁴ at December 31, 2025, and is expected to be utilized by May 31, 2027 ⁷⁵. The company plans to finance future operations through a combination of public or private equity offerings, debt financings, or other capital sources, such as potential collaboration agreements ⁷⁶. As of December 31, 2025, the company had estimated commitments of $18.7 million ⁷⁷ related to open purchase orders and contractual obligations for multi-year preclinical and clinical research studies ⁷⁸.

Management has explicitly flagged that there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and dependence on additional financing ⁷⁹. The company's ability to raise capital on acceptable terms, or at all, is uncertain ⁸⁰. Failure to obtain sufficient funding could force the company to significantly reduce operating plans and curtail product development activities ⁸¹. The company also faces risks related to the lengthy, time-consuming, and unpredictable regulatory approval processes, and the possibility that clinical trials may not replicate earlier positive results ⁸². Competitive products, including those from major pharmaceutical and biotechnology companies with significantly greater resources, may reduce or eliminate commercial opportunities for its product candidates ⁸³.

The company faces substantial doubt about its ability to continue as a going concern due to recurring losses from operations and dependence on additional financing ⁸⁴. There is a risk that the company's lead product candidates, PF614 and PF614-MPAR, may not be successful in limiting or impeding abuse, overdose, or misuse, or providing additional safety upon commercialization ⁸⁵. The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no assurance that clinical trials will be conducted as planned or completed on schedule ⁸⁶. The FDA may disagree with the company's regulatory plan, and interim or preliminary clinical data may change as more patient data become available ⁸⁷. The company is completely dependent on third parties to manufacture its product candidates, and any failure by these third parties to maintain compliance or provide sufficient quantities could halt or delay commercialization ⁸⁸. Oxycodone, an ingredient in PF614, is a Schedule II controlled substance, subjecting the company to strict DEA regulations and annual quotas, which if not met, could negatively impact the business ⁸⁹. The company's commercial success depends on obtaining and maintaining patent protection, and there is a risk that patents may not be issued, may be found invalid or unenforceable, or may be circumvented by competitors ⁹⁰. The company may face litigation from third parties claiming intellectual property infringement, or seeking to challenge the validity of its patents, which could be expensive and time-consuming ⁹¹. Cyber-attacks or other failures in IT systems, or those of collaborators, could result in information theft, data corruption, and significant business disruption ⁹². Raising additional capital through equity offerings will cause dilution to stockholders, and debt financing may include restrictive covenants ⁹³. The company is not in compliance with Nasdaq's bid price requirement and faces a risk of delisting, which could adversely affect liquidity and ability to raise funding ⁹⁴.

Management's overall tone emphasizes the company's commitment to developing innovative solutions for severe pain relief while addressing opioid misuse, abuse, and overdose through its TAAP and MPAR® platforms. They acknowledge the significant financial losses incurred since inception and the ongoing need for substantial additional funding to continue operations and advance product candidates ⁹⁵. Management explicitly states that existing cash and cash equivalents are expected to fund operations into the second quarter of 2026 ⁹⁶, highlighting the critical need for future financing. Key strategic priorities include aggressively pursuing advanced clinical-stage product candidates like PF614 and PF614-MPAR, ensuring the development of additional potential product candidates, and obtaining regulatory approvals ⁹⁷. They also stress the importance of obtaining an abuse-deterrent label for their prodrugs, which they believe would provide a significant competitive advantage ⁹⁸.